LONDON--(BUSINESS WIRE)--The global vaccines market is expected to grow by USD 13.81 billion as per Technavio. This marks a significant market slowdown compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, healthy growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 7%. Request free sample pages
Read the 160-page report with TOC on "Vaccines Market Analysis Report by Type (Prophylactic vaccines and Therapeutic vaccines) Geographic Landscape (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024".
The market is driven by the increasing use of adjuvants in vaccines. In addition, the development of nanoparticle vaccines is anticipated to boost the growth of the vaccines market.
Researchers are continuously developing vaccines to fight emerging new pathogens and re-emerging old pathogens. As a result, they are selecting and using suitable adjuvants that are crucial in enhancing the vaccine potency. Adjuvants such as immunologic adjuvants improve the humoral and cell-mediated immune response to vaccine antigens. Thus, the increasing use of adjuvants for developing high-efficacy vaccines is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Vaccines Companies:
Bavarian Nordic AS
Bavarian Nordic AS is headquartered in Denmark and operates the business under the Pharmaceuticals segment. The company offers IMVAMUNE/IMVANEX, which is an MVA-BN non-replicating smallpox vaccine.
CSL Ltd. is headquartered in Australia and offers products through the following business units: CSL Behring and Seqirus. The company develops vaccines such as AFLURIA, FLUCELVAX, FLUAD, and FLUCELVAX TETRA.
Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is headquartered in the US and operates under the Pharmaceuticals business segment. The company develops vaccines such as ACAM2000, BioThrax, VAXCHORA, and Vivotif.
GlaxoSmithKline Plc is headquartered in the UK and offers products through the following business segments: Pharmaceuticals, Vaccines, and Consumer healthcare. The company offers vaccines such as Ambirix, BEXSERO, BOOSTRIX, and CERVARIX.
Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc. is headquartered in the US and offers products through the Biopharmaceuticals business segment. The company offers vaccines such as VGX-3100 and PENNVAX-GP.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Vaccines Market Type Outlook (Revenue, USD Billion, 2020-2024)
- Prophylactic vaccines
- Therapeutic vaccines
Vaccines Market Geographic Landscape Outlook (Revenue, USD Billion, 2020-2024)
- North America
- Key leading countries
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care are:
Therapeutic Vaccines Market – Global Therapeutic Vaccines Market by type (cancer vaccines, infectious diseases vaccines, neurological diseases vaccines, autoimmune diseases vaccines, and other diseases vaccines) and geography (Asia, Europe, North America, and ROW).
Japanese Encephalitis Vaccines Market – Global Japanese Encephalitis Vaccines Market by type (Inactivated vaccines, recombinant vaccines, and live attenuated vaccines) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.